The good news from Biogen’s (BIIB) Q2 exciting financial results comprised impressive news for Ionis (IONS) from the commercialization of Ionis’ approved product, Spinraza for Spinal muscular atrophy (SMA). Biogen is also responsible for the commercialization of Ionis’ products Tegsedi™ (inotersen) and Waylivra™ (volanesorsen) – two antisense drugs that Ionis discovered and successfully advanced through Phase 3 studies.
In the second quarter of Biogen’s 2018 financial report, Spinraza sales’ revenues were $206 million in the U.S. and $217 million . . .
This content is for paid subscribers.
Today’s Highlights July 24, 2018